Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Distance Corrections01:15

Distance Corrections

293
To achieve precise distance measurements, especially in surveying and construction, certain corrections must be applied to account for potential sources of error like the standardization errors, temperature variations, and slope adjustments.Standardization error emerges when measurement equipment undergoes changes, such as wear, repairs, or weather impacts. To address this, surveyors compare the equipment’s readings to a standard. This process identifies any deviation that might lead to...
293
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

279
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
279
Power Factor Correction01:20

Power Factor Correction

544
The power transmission to a factory involves the transfer of apparent power, a combination of active and reactive power. The power factor measures how effectively electrical power is converted into useful work output. The ratio of the real power (KW) that does the work to the apparent power (KVA) supplied to the circuit.
544
NMR Spectrometers: Resolution and Error Correction01:14

NMR Spectrometers: Resolution and Error Correction

1.1K
When magnetic nuclei in a sample achieve resonance and undergo relaxation, the signal detected in NMR is an approximately exponential free induction decay. Fourier transform of an exponential decay yields a Lorentzian peak in the frequency domain. Lorentzian peaks in an NMR spectrum are defined by their amplitude, full width at half maximum, and position, where the peak width is governed by the spin-spin relaxation time alone. In real experiments, however, the applied magnetic field is rendered...
1.1K
Proofreading01:43

Proofreading

61.4K
Overview
61.4K
tRNA Activation02:26

tRNA Activation

23.0K
Aminoacyl-tRNA synthetases are present in both eukaryotes and bacteria. Though eukaryotes have 20 different aminoacyl-tRNA synthetases to couple to 20 amino acids, many bacteria do not have genes for all of these aminoacyl-tRNA synthetases. Despite this, they still use all 20 amino acids to synthesize their proteins. For instance, some bacteria do not have the gene encoding the enzyme that couples glutamine with its partner tRNA. In these organisms, one enzyme adds glutamic acid to all of the...
23.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Abrocitinib: First Approval.

Drugs·2022
Same author

Asciminib: First Approval.

Drugs·2022
Same author

Chiglitazar: First Approval.

Drugs·2021
Same author

Atogepant: First Approval.

Drugs·2021
Same author

Abrocitinib: First Approval.

Drugs·2021
Same author

Casirivimab/Imdevimab: First Approval.

Drugs·2021

Related Experiment Video

Updated: Feb 7, 2026

Surgical Correction for Pediatric Epiblepharon and Trichiasis
03:59

Surgical Correction for Pediatric Epiblepharon and Trichiasis

Published on: July 8, 2025

599

Correction to: GP2015: An Etanercept Biosimilar.

Emma D Deeks1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

GP2015, an etanercept biosimilar, is now available as an open access publication. This allows for broader dissemination of information regarding this therapeutic option.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
05:46

Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity

Published on: September 20, 2024

825

Related Experiment Videos

Last Updated: Feb 7, 2026

Surgical Correction for Pediatric Epiblepharon and Trichiasis
03:59

Surgical Correction for Pediatric Epiblepharon and Trichiasis

Published on: July 8, 2025

599
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
05:46

Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity

Published on: September 20, 2024

825

Area of Science:

  • Pharmacology
  • Biotechnology
  • Immunology

Background:

  • Etanercept is a biologic medication used to treat autoimmune diseases.
  • Biosimilars offer potential alternatives to originator biologics, increasing accessibility.
  • GP2015 is a biosimilar developed for etanercept.

Purpose of the Study:

  • To provide information on GP2015, an etanercept biosimilar.
  • To facilitate wider access to research on biosimilar etanercept.

Main Methods:

  • The article was originally published online and subsequently made open access.
  • Funding for open access publication was provided by HEXAL AG.

Main Results:

  • The article detailing GP2015 is now accessible under a Creative Commons license.
  • This ensures non-commercial use, distribution, and adaptation with proper attribution.

Conclusions:

  • GP2015, an etanercept biosimilar, is now openly available.
  • Open access promotes wider knowledge sharing and utilization of biosimilar therapies.